News Vaxart, Inc.

Equities

VXRT

US92243A2006

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
0.7289 ^USD	-2.68%		+2.71%	+27.25%

Mar. 14	Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 14	Transcript : Vaxart, Inc., 2023 Earnings Call, Mar 14, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers	Apr. 30	AQ
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3	Mar. 27	AQ
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 20	AQ
Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Transcript : Vaxart, Inc., 2023 Earnings Call, Mar 14, 2024	Mar. 14
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results	Mar. 14	AQ
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14	Mar. 07	AQ
Vaxart Appoints Steven Lo as Chief Executive; Shares Fall	Mar. 06	MT
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director	Mar. 06	AQ
Vaxart, Inc. Announces Chief Executive Officer Changes	Mar. 06	CI
Vaxart, Inc. Announces Management Appointments	Mar. 06	CI
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge	Feb. 05	AQ
North American Morning Briefing : Stock Futures -2-	Feb. 01	DJ
B. Riley Upgrades Vaxart to Buy From Neutral, Lifts PT to $2 From $1.50	Jan. 31	MT
Vaxart Secures $9.3 Million Award for Phase 2b COVID-19 Pill Study	Jan. 19	MT
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate	Jan. 19	AQ
Vaxart to Raise $10 Million From RA Capital Management; Shares Rise	Jan. 16	MT
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management	Jan. 16	AQ
Vaxart, Inc. Announces Management Change	Jan. 16	AQ
Vaxart, Inc. Announces CEO Changes	Jan. 16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Vaxart, Inc.

Equities

VXRT

US92243A2006

Summary

Filters